2020年4月9日 · CD49d is a remarkable prognostic biomarker of chronic lymphocytic leukemia (CLL). The cutoff value for the extensively validated 30% of positive CLL cells is able to separate CLL patients into 2 subgroups with different prognoses, but it does not consider the pattern of CD49d expression.

2010年7月1日 · We found CD49d (VLA4), a member of the integrin α-chain family of proteins, to be exclusively expressed on CD11b + Gr-1 dull/int cells. CD49d is composed of a α4 (CD49d) and a β1 (CD29) chain and serves as a receptor for fibronectin and VCAM-1 (VCAM-1, CD106).

2025年3月3日 · Persistently reduced expression of blood monocyte CD49e is an adverse prognostic marker in HIV (AIDS 2009;23:2247) Uses by pathologists. No significant clinical use by pathologists Immunofluorescence images Contributed by Vincent Achard, M.D., Ph.D.

2023年11月2日 · Here, we address the consequences of genetic B cell-specific ablation of CD49d on disease development, engraftment capacity and treatment susceptibility in a novel CLL mouse model.

2000年10月15日 · CD49d integrin expression conferred mature MDDC with an elevated capacity to adhere to the CS-1 fragment of fibronectin, and also mediated transendothelial migration of mature MDDC. Up-regulation of CD49d integrin expression closely paralleled that of the mature DC marker CD83.

2008年1月15日 · CD49d/α4-integrin is variably expressed in chronic lymphocytic leukemia (CLL). We evaluated its relevance as independent prognosticator for overall surviva

We analyzed CD49d expression in 140 consecutive Binet A chronic lymphocytic leukemia. At diagnosis, CD49d ≥30% (54/140, 38.6%) associated with proliferation markers, namely CD38 ≥30% (p =3.9×10 −6), LDH (p =0.007) and β2-microglobulin (p =0.020).

In conclusion, surface expression of CD49d and CD26 are independent adverse prognostic markers in patients with CLL at different stages. Therefore, evaluation of CD26 and CD49d expression is suggested as a part of routine future panel for prognostic stratification of CLL patients at diagnosis.

2013年11月28日 · A more recently discovered marker is CD49d, the alpha4 subunit of the VLA-4 integrin (alpha4beta1). High CD49d expression predicts reduced overall survival and time to first treatment in CLL patients [ 10 , 11 ].

2009年11月20日 · In chronic lymphocytic leukemia (CLL), CD49d, often in association with CD38, has been shown to mark a disease subset with poor prognosis. Functionally, both molecules act as counter-receptors for surface structures (i.e. VCAM-1/CD106 and CD31) usually expressed by the endothelial/stromal component of tumor micro-environment.